Lipocine Inc. (LPCN)

NCM – Real vaqt narxi. Valyuta: USD

2.09

0.00 (0.00%)

Bozor ochiq: Aug 12, 2026, 2:27 PM EDT

2.09

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 4:10 PM EDT

04.08.2026

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended June 30, 2026 and provided a corporate update. Recent Developments and Corporate Update LPCN 1154 (BRLIZIO™) for Postpartum Depression (PPD) On April 2, 2026, Lipocine reported topline results from its Phase 3 placebo-controlled trial (N=90) evaluating oral LPCN 1154 (oral brexanolone) for the treatment of PPD.

03.08.2026

Lipocine Appoints Michael J. Grissinger to Board of Directors

SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

04.08.2026

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

03.08.2026

Lipocine Inc. (LPCN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Lipocine Inc. (LPCN)

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Appoints Michael J. Grissinger to Board of Directors

Videolar

No Data

Press-relizlar

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Appoints Michael J. Grissinger to Board of Directors

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Appoints Michael J. Grissinger to Board of Directors

Videolar

No Data

Press-relizlar

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Appoints Michael J. Grissinger to Board of Directors

Search stocks

Lipocine Inc. (LPCN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Lipocine Inc. (LPCN)

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Appoints Michael J. Grissinger to Board of Directors

Videolar

No Data

Press-relizlar

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Appoints Michael J. Grissinger to Board of Directors

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Appoints Michael J. Grissinger to Board of Directors

Videolar

No Data

Press-relizlar

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Appoints Michael J. Grissinger to Board of Directors